The mutational landscape of lethal castration-resistant prostate cancer

Nature

Volumn 487, Issue 7406, 2012, Pages 239-243

  Grasso, Catherine S ^a   Wu, Yi Mi ^a   Robinson, Dan R ^a   Cao, Xuhong ^a   Dhanasekaran, Saravana M ^a   Khan, Amjad P ^a   Quist, Michael J ^a   Jing, Xiaojun ^a   Lonigro, Robert J ^a   Brenner, J Chad ^a   Asangani, Irfan A ^a   Ateeq, Bushra ^a   Chun, Sang Y ^a   Siddiqui, Javed ^a   Sam, Lee ^a   Anstett, Matt ^b   Mehra, Rohit ^a   Prensner, John R ^a   Palanisamy, Nallasivam ^a   Ryslik, Gregory A ^c   Vandin, Fabio ^d   Raphael, Benjamin J ^d   Kunju, Lakshmi P ^a   Rhodes, Daniel R ^a,b   Pienta, Kenneth J ^a   Chinnaiyan, Arul M ^a   Tomlins, Scott A ^a   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Departments of Compendia Bioscience   (United States)

^c YALE UNIVERSITY   (United States)

^d Brown Univerity   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA;

ANDROGEN; CANCER; CASTRATION; CHROMOSOME; GENOME; MUTATION; PRIORITIZATION;

ARTICLE; AUTOPSY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; EXOME; GENE DELETION; GENE DOSAGE; GENE FUSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; CELLS, CULTURED; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

EID: 84863723010     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11125     Document Type: Article

References (23)

1. Shen, M. M. & Abate-Shen, C. Moleculargeneticsofprostatecancer: newprospects for old challenges. Genes Dev. 24, 1967-2000 (2010).
2. Kumar, A. et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl Acad. Sci. USA 108, 17087-17092 (2011).
3. Robbins, C. M. et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumours. Genome Res. 21, 47-55 (2010).
4. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
5. Attard, G., Reid, A. H., Olmos, D. & de Bono, J. S. Antitumour activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69, 4937-4940 (2009).
6. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations inhuman cancers. Nature 466, 869-873 (2010).
7. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
8. Rubin, M. A. et al. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin. Cancer Res. 6, 1038-1045 (2000).
9. Lonigro, R. J. et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 13, 1019-1025 (2011).
10. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
11. Wei, G. H. et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 29, 2147-2160 (2010).
12. Demichelis, F. et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosom. Cancer 48, 366-380 (2009).
13. Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337-8341 (2006).
14. Yoshimoto, M. et al. Three-color FISHanalysis ofTMPRSS2/ERGfusions in prostate cancer indicates that genomicmicrodeletionof chromosome21is associatedwith rearrangement. Neoplasia 8, 465-469 (2006).
15. Yu, X. et al. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann. NY Acad. Sci. 1061, 77-93 (2005).
16. Yu, J. et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERGgene fusions in prostate cancer progression. Cancer Cell 17, 443-454 (2010).
17. Gao, N. et al. The role of hepatocyte nuclear factor-3 a (forkhead box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 17, 1484-1507 (2003).
18. Wang, Q. et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27, 380-392 (2007).
19. Wang, Q. et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245-256 (2009).
20. Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958-970 (2008).
21. Sahu, B. et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 30, 3962-3976 (2011).
22. Zhang, C. et al. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res. 71, 6738-6748 (2011).
23. Werner, M. H. et al. Correction of the NMR structure of the ETS1/DNA complex. J. Biomol. NMR 10, 317-328 (1997).